Compare Organon & Co. Common Stock (OGN) vs Unilever plc (UL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs Unilever plc — how do they compare? Organon & Co. Common Stock trades at $13.73 (market cap $3.61B), while Unilever plc trades at $65 (market cap $137.84B). The key difference: Unilever plc is far larger — about 38.2× Organon & Co. Common Stock's market cap, and Unilever plc pays the higher dividend (3.32%). Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and Unilever plc for 112 Days on average.
| OGN | UL | |
|---|---|---|
Market Cap | $3.61B | $137.84B |
Volume | 1,808,049 | 2,711,415 |
Sector | Health | Consumer Staples |
52-Week High | $13.81 | $74.59 |
52-Week Low | $5.70 | $55.05 |
Typical Hold Time | 0 Days | 112 Days |
Enterprise Value | $11.03B | $162.87B |
Dividend Yield | 0.58% | 3.32% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Unilever (UL) trades at $62.49, down 0.73% with a bullish technical signal despite recent earnings misses. The company shows strong profitability with 18.32% net margins and 54.56% ROE, though revenue declined to $50.5B in 2025. Recent news highlights the planned $65B food business merger with McCormick facing regulatory scrutiny while the company focuses on beauty and personal care segments.
UL presents a mixed outlook with strong fundamentals offset by execution risks. The 26.32% buy rating and $66.08 consensus target suggest modest upside potential, but investors face headwinds from competitive pressures and integration challenges from the McCormick deal. The stock's current valuation at 21.87 P/E appears reasonable given its defensive characteristics and emerging market exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About Unilever plc
Unilever is a diversified personal product (42% of 2021 sales by value), home care (20%), and packaged food (38%) company. Its brands include Knorr soups and sauces, Hellmann's mayonnaise, Lipton teas, Axe and Dove skin products, and the TRESemme haircare brand. The firm has been acquisitive in recent years
Read more on UL →
